Cormorant Asset Management’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Cormorant Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.5M	Buy	+1,525,000	New	+$39.2M	1.98%	16
2023 Q3	–	Sell	-40,810	Closed	-$2.57M	–	59
2023 Q2	$2.57M	Hold	40,810	–	–	0.14%	58
2023 Q1	$2.03M	Hold	40,810	–	–	0.13%	60
2022 Q4	$1.17M	Hold	40,810	–	–	0.08%	63
2022 Q3	$1.93M	Hold	40,810	–	–	0.13%	62
2022 Q2	$1.76M	Hold	40,810	–	–	0.13%	63
2022 Q1	$2.25M	Hold	40,810	–	–	0.17%	63
2021 Q4	$3.09M	Sell	40,810 -5,219	-11%	-$410K	0.18%	65
2021 Q3	$4.13M	Sell	46,029 -24,125	-34%	-$2.58M	0.17%	74
2021 Q2	$8.87M	Sell	70,154 -15,875	-18%	-$2.16M	0.3%	67
2021 Q1	$13.1M	Hold	86,029	–	–	0.29%	65
2020 Q4	$26.5M	Buy	+86,029	New	+$32M	0.63%	39

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Cormorant Asset Management's DMRA Position: Q1 2026 in Review

Cormorant Asset Management opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 1,525,000 shares worth $39.5M. The stake represents 1.98% of the portfolio and ranks #16 among its holdings. This is a return to the name: Cormorant Asset Management previously reported a position in DMRA as recently as Q2 2023.

Cormorant Asset Management first reported a position in DMRA in Q4 2020 and has held it in 12 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Cormorant Asset Management held 1,525,000 shares of Damora Therapeutics, Inc. Ordinary Shares worth $39.5M as of Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares was a new Cormorant Asset Management position in Q1 2026.
Damora Therapeutics, Inc. Ordinary Shares made up 1.98% of Cormorant Asset Management's portfolio in Q1 2026, its #16 holding.
Cormorant Asset Management first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2020 and has held it in 12 quarters since.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.